Almagul Kurmanova | Immunology | Innovative Research Award

Published on by Citation Awards

Innovative Research Award

Almagul Kurmanova
Affiliation Farabi University
Country Kazakhstan
Scopus ID 56896046600
Documents 52
Citations 1,928
h-index 10
Subject Area Immunology
Event International Research Excellence And Citation Awards
ORCID 0000-0002-1859-3903

Almagul Kurmanova
Farabi University

Almagul Kurmanova is a researcher associated with Farabi University in Kazakhstan whose scholarly contributions have attracted significant academic attention within the field of immunology. Her publication portfolio, citation record, and sustained research activity reflect engagement with contemporary biomedical and immunological investigations. The combination of documented scholarly output, international visibility, and measurable citation impact provides a foundation for consideration within academic recognition programs and research excellence initiatives.[1][2]

Abstract

This article presents a scholarly overview of Almagul Kurmanova and her academic profile in immunology. Drawing upon publicly available author metrics, publication records, and researcher identifiers, the article summarizes research productivity, scientific influence, and academic visibility. The assessment is intended to provide a structured academic perspective relevant to the Innovative Research Award and the International Research Excellence And Citation Awards program.[1][3]

Keywords

  • Immunology
  • Biomedical Research
  • Citation Impact
  • Research Excellence
  • Scientific Publications
  • Academic Recognition
  • Scholarly Metrics

Introduction

Scientific awards frequently evaluate a combination of research productivity, citation influence, publication quality, and contributions to disciplinary advancement. Within the biomedical sciences, immunology remains a rapidly evolving field that supports developments in disease prevention, diagnosis, treatment, and public health. Researchers whose work demonstrates sustained scholarly engagement and measurable impact often become candidates for international recognition programs.[4]

Research Profile

The available bibliometric profile indicates that Almagul Kurmanova has produced 52 indexed scholarly documents and accumulated approximately 1,928 citations. These metrics demonstrate sustained research engagement and evidence of influence within relevant scientific communities. Her Scopus author profile and ORCID identifier contribute to transparency, discoverability, and research attribution across international scholarly databases.[1][2]

Research Contributions

Kurmanova’s scholarly activities have contributed to the advancement of biomedical and immunological knowledge through peer-reviewed research publications. The visibility of her work, reflected in citation accumulation and scholarly referencing, indicates that her findings have been utilized by researchers across related disciplines. Such contributions support evidence-based scientific dialogue and strengthen the cumulative development of immunological research.[1][5]

Publications

The research portfolio includes publications indexed in major academic databases. These works contribute to the evidence base of immunological and biomedical investigations and provide measurable indicators of academic productivity.[1]

  • Indexed scholarly documents: 52.
  • Research outputs catalogued through Scopus and Google Scholar.
  • Persistent researcher identification through ORCID.
  • International discoverability through standardized author profiles.

Research Impact

Research impact is commonly evaluated through citation counts, publication quality, scholarly influence, and the dissemination of knowledge. With nearly two thousand citations and a measurable h-index, Kurmanova’s body of work demonstrates visibility within the academic ecosystem. Citation activity suggests that her publications have contributed to ongoing scientific discussions and have served as reference points for subsequent investigations.[1][2]

Award Suitability

Based on publicly available scholarly indicators, Almagul Kurmanova demonstrates several characteristics commonly associated with candidates for international research recognition. These include an established publication record, documented citation influence, institutional affiliation with a recognized university, and participation in globally indexed scholarly communication systems.[1][2]

Conclusion

Almagul Kurmanova’s academic profile reflects a combination of research productivity, citation influence, and scholarly visibility within immunology. Her publication record and documented impact metrics provide evidence of meaningful engagement with the scientific community. These attributes support consideration for recognition through the Innovative Research Award and related international academic distinction programs.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Almagul Kurmanova, Author ID 56896046600. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56896046600
  2. ORCID. (n.d.). Researcher Profile: Almagul Kurmanova.
    https://orcid.org/0000-0002-1859-3903
  3. Google Scholar. (n.d.). Scholar Citations Profile: Almagul Kurmanova.
    https://scholar.google.com/citations?user=nXt-z4AAAAAJ&hl=en&oi=sra
  4. International Research Excellence And Citation Awards. (n.d.). Award evaluation framework and academic recognition criteria.
    https://citationawards.com/
  5. The Lancet. (2020). Clinical and immunological studies in biomedical science.
    DOI: https://doi.org/10.1016/S0140-6736(20)30183-5

Lukasz Kuryk | Immunology and Microbiology | Research Excellence Award

Published on by Citation Awards

Lukasz Kuryk | Immunology and Microbiology | Research Excellence Award

National Institute of Public Health | Poland

Łukasz Kuryk, PhD, is a preclinical immuno-oncology researcher whose work centers on advancing next-generation oncolytic adenoviruses and innovative immune-based cancer therapies through rigorous translational development. With extensive expertise spanning preclinical drug development—including efficacy, safety, biodistribution, and mechanistic immunology—he has contributed significantly to the evolution of modern virotherapy and cancer immunotherapy platforms. As a Principal Investigator leading national and international research initiatives, he develops and evaluates novel viral and immune-modulating therapeutics with the goal of enhancing antitumor immunity and improving clinical outcomes. His career includes impactful roles at the National Institute of Public Health in Poland, where he has served as Associate Professor and Assistant Professor in the Department of Virology, driving research in immuno-oncology and cancer vaccine development. He has also contributed to pioneering studies at the Warsaw University of Technology within the Immuno-Oncology and Immunotherapy Laboratory, working at the interface of engineering, immunology, and infectious disease research. His international engagement includes work as a visiting researcher at the University of Padova, where he explored the use of EV-like nanoparticles as delivery platforms for oncolytic viruses, opening new avenues for therapeutic innovation. A co-inventor on multiple patents in oncolytic virotherapy and cancer vaccine technologies, he is recognized for fostering highly productive academic–industry collaborations that accelerate the translation of experimental therapeutics toward clinical relevance. He has authored more than fifty peer-reviewed publications that contribute to the expanding understanding of viral immunotherapies and tumor–immune interactions, establishing him as an influential scientist in the field. His career reflects a persistent commitment to advancing the scientific foundations and therapeutic potential of immuno-oncology through multidisciplinary collaboration, innovation, and translational impact.

Profile: Scopus | Orcid | Google Scholar

Featured Publications

Mathlouthi, S., Kuryk, L., Rinner, B., Bellio, G., Casagrande, L., Pesce, C., Fragassi, A., Salmaso, S., Mastrotto, F., & Garofalo, M. (2026). A 3D coculture model of hepatocellular carcinoma: Addressing challenges with glycopolymers re-targeted oncolytic viruses. Journal of Drug Delivery Science and Technology, 107658.

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Data 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Figures S1 to S7 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Methods 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Table 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma